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Abstract
Background: The quaternary isoquinoline alkaloid sanguinarine is receiving increasing attention
as a potential chemotherapeutic agent in the treatment of cancer. Previous studies have shown that
this DNA-binding phytochemical can arrest a number of different types of transformed cells in G0/
G1, and upregulate the CKIs p21 and p27 while downregulating multiple cyclins and CDKs. To
more closely examine the responses of some of these cell cycle regulatory molecules to
sanguinarine, we used immunocytochemical methods to visualize cyclin D1 and topoisomerase II
behavior in MCF-7 breast cancer cells.
Results: 5 – 10 µM sanguinarine effectively inhibits MCF-7 proliferation after a single application
of drug. This growth inhibition is accompanied by a striking relocalization of cyclin D1 and
topoisomerase II from the nucleus to the cytoplasm, and this effect persists for at least three days
after drug addition. DNA synthesis is transiently inhibited by sanguinarine, but cells recover their
ability to synthesize DNA within 24 hours. Taking advantage of the fluorescence characteristics of
sanguinarine to follow its uptake and distribution suggests that these effects arise from a window
of activity of a few hours immediately after drug addition, when sanguinarine is concentrated in the
nucleus. These effects occur in morphologically healthy-looking cells, and thus do not simply
represent part of an apoptotic response.
Conclusion: It appears that sub-apoptotic concentrations of sanguinarine can suppress breast
cancer cell proliferation for extended lengths of time, and that this effect results from a relatively
brief period of activity when the drug is concentrated in the nucleus. Sanguinarine transiently
inhibits DNA synthesis, but a novel mechanism of action appears to involve disrupting the
trafficking of a number of molecules involved in cell cycle regulation and progression. The ability of
sub-apoptotic concentrations of sanguinarine to inhibit cell growth may be a useful feature for
potential chemotherapeutic applications; however, a narrow effective range for these effects may
exist.
Background
Investigation into the mechanisms of action of plant-
derived compounds remains an important approach in
the search for new and more effective anti-cancer agents.
Productive sources of chemopreventative and chemother-
apeutic phytochemicals include plants and plant products
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associated with the diet and with traditional medicinal
approaches. Significant work has been conducted on spe-
cies used in traditional Chinese and Ayurvidic medicine,
but comparatively little attention has been paid to plants
used in traditional Native American medicine. To learn
more about these types of phytochemicals, we examined
the effects of a number of terpenes and alkaloids present
in traditional Native American medicine preparations.
Ursolic and oleanolic acids, berberine, and sanguinarine
were initially studied because they are prominent compo-
nents in a number of plant species used in these practices.
For example, a syrup called "was-a-mos," composed of the
roots of spiken, sweet fern, yellow dock, elecampane, ver-
vain, pigeon cherry, white pine bark, and bloodroot was
used by the Green Bay Indians to treat cancer [1]. In addi-
tion, tribes such as the Cherokee, East Coast, and Lake
Superior Indians utilized bloodroot extensively as a dye in
body paint for ritual ceremonies, and in traditional med-
icine to treat sore throats, cough, rheumatoid arthritis and
various cancers. Our preliminary results, together with
other published works, indicated that sanguinarine is par-
ticularly interesting in terms of possible chemotherapeu-
tic applications.
Sanguinarine (13-methyl benzodioxolo{5,6-c}-1,3-diox-
olo{4,5-i}phenanthridinium) is an benzophenanthrid-
ine alkaloid derived from the root of Sanguinaria
canadensis and other poppy-fumaria species, and has been
shown to possess antimicrobial, anti-inflammatory, and
antioxidant properties. Structurally related alkaloids are
already important chemotherapeutics in the treatment of
cancer, including irinotecan and topotecan [2]. Sangui-
narine can block proliferation and induce apoptosis in a
number of different transformed and malignant cell types
[3-5]. Of particular interest from a chemotherapeutic
standpoint, sanguinarine suppresses the growth of squa-
mous carcinoma cells more effectively than normal fore-
skin keratinocytes [6], and inhibits the growth of a
number of multidrug resistant cell lines [5].
Sanguinarine exerts multiple effects within cells, includ-
ing reacting with nucleophilic and anionic groups of
amino acids; binding to microtubules [7]; inhibiting cer-
tain protein kinases and phosphatases [8,9], NF-kB [10],
Na+, K+-ATPase, succinate dehydrogenase and NADH
dehydrogenase [11,12]; altering mitochondrial respira-
tion and uncoupling oxidative phosphorylation [13];
forming labile covalent bonds with SH groups and inhib-
iting SH-containing proteins [14]; intercalating into GC-
rich regions of DNA [15,16]; and inhibiting reverse tran-
scriptase and DNA synthesis [17]. With respect to effects
on the proliferative ability of malignant cells, sanguinar-
ine has been reported to arrest the cell cycle and increase
the percentage of cells in G0/G1. These effects are accom-
panied by an increase in cyclin-dependent protein kinase
inhibitor (CKI) expression and a decrease in cyclin D1, D2
and E, and CDK2, 4 and 6 quantity [4]. The closely related
alkaloid coptisine has been reported to impart a double
G1 and G2/M block, and also suppresses the quantity of
cyclin D1 [18]. Similar effects have been noted for certain
triterpenoids, such as CDDO (2-cyano-3,12-dioxooleana-
1,9-dien-28-oic acid). Differential cDNA array analyses
indicate that p21Waf1/Cip1 is up-regulated by CDDO treat-
ment, and that cyclin D1 and proliferating cell nuclear
antigen (PCNA) are down-regulated [19]. Both coptisine
and CDDO promote proteasome-mediated destruction of
cyclin D1, and threonine 286 of cyclin D1 is critical in
CDDO-mediated proteolysis [18,20]. CDDO, but not
coptisine, also promotes cyclin E proteolysis [18,20], sug-
gesting that these compounds exert distinct effects on dif-
ferent cyclin/CDK family members.
A number of different alkaloids are potent inhibitors of
topoisomerase activity. The best known examples are
derivatives of camptothecin, but a number of novel iso-
quinoline alkaloids are receiving increasing attention,
including Ecteinascidin-743, Phthalascidin, Lamellarin D,
and Tetrandrine [21-25]. Interestingly, triterpenoids
somewhat similar in structure to sanguinarine have also
been shown to also inhibit topoisomerase activity [26-
30]. These compounds exhibit cytotoxicity toward a
number of different tumor cell types, including neurob-
lastoma [31], brain [32], skin [33] and melanoma cells
[34].
Although studies to date indicate that cyclin quantity and
topoisomerase activity are affected by certain phytochem-
icals, little is known about the detailed behavior of these
cell cycle-associated molecules during exposure to these
compounds. For example, it has been shown that relocal-
ization of topoisomerases within the cell can be a critical
factor in the response to topoisomerase poisons [35,36].
These observations suggest that sanguinarine and related
molecules should be more closely examined for their
effects on the overall behavior of cyclins, topoisomerases,
and other cell cycle regulatory molecules in malignant
cells. For this purpose, we treated MCF-7 breast cancer
cells with sub-apoptotic doses of sanguinarine and stud-
ied cyclin D1 and topoisomerase II behavior by immuno-
cytochemical methods. We found that sanguinarine
induces a striking disruption of normal cyclin and topoi-
somerase II trafficking, which may represent an important
part of the mechanism by which this phytochemical sup-
presses the proliferation of transformed cells.
Results
Dose-response studies indicate that concentrations of 2.5
µM and higher sanguinarine suppress the growth of MCF-
7 cells (Fig. 1). There appears to be a relatively narrow
window of growth-suppressive activity, with concentra-BMC Cell Biology 2006, 7:13 http://www.biomedcentral.com/1471-2121/7/13
Page 3 of 12
(page number not for citation purposes)
tions less than 2.5 µM exhibiting little effect, and 10 µM
or higher resulting in a significant level of cell death in this
cell line (data not shown). In addition, the effectiveness of
sanguinarine is strongly influenced by cell density, with
higher density cultures exhibiting a noticeable resistance
to the same concentrations of sanguinarine effective in
lower density cultures. Under the conditions used for this
study, a single dose of 5 µM sanguinarine essentially com-
pletely suppressed MCF-7 proliferation for at least six days
(Fig. 1), while inducing only modest levels of cell death.
To test for effects on certain cell cycle regulatory mole-
cules, cultures were treated with 5 µM sanguinarine, fixed,
and immunolabeled with various antibodies. Interest-
ingly, changes in the localization patterns of cyclin D1
and topoisomerase II were noted. In control cells, cyclin
D1 immunoreactivity is largely restricted to nuclei, which
exhibit a range of labeling intensities (Fig. 2a–c). In cul-
tures treated with 5 µM sanguinarine for 24 hours, how-
ever, punctate cytoplasmic deposits of immunoreactive
material are evident, along with a general decrease in
nuclear labeling (Fig. 2d–f). To test how persistent this
cytoplasmic relocalization of cyclin D1 is, cells were
treated with sanguinarine for 24 hours, followed by drug
removal and recovery for 48 hours in drug-free medium.
These experiments demonstrate that cytoplasmic foci of
cyclin D1 are still present in many cells after two days of
drug recovery (Fig. 2g–i).
The distribution of topoisomerase II is also altered follow-
ing sanguinarine treatment (Fig. 3). In control cells, topoi-
somerase II immunoreactivity is weakly distributed
throughout the cytoplasm, and is also present in the
nucleus of many cells; some cells display very strong
nuclear labeling (Fig. 3a–c). Similar to the results for cyc-
lin D1, cytoplasmic deposits of topoisomerase II become
apparent after 24 hours of treatment with 5 µM sanguinar-
ine (Fig. 3e–g). In many cultures, this redistribution of
topoisomerase II is even more pronounced than that of
cyclin D1. Careful examination of double-labeled cells
indicates that most, but not all, of the cyclin D1 and
topoisomerase cytoplasmic immunoreactive foci appear
to be co-localized.
To examine whether sanguinarine causes a non-specific
redistribution of nuclear proteins in general, cultures were
also labeled with antibodies to the nuclear matrix proteins
lamin B1 and NuMA. Changes in the location or overall
labeling pattern were not evident for either NuMA (Fig.
3d,h) or lamin B1 (not shown) in sanguinarine-treated
cultures.
We then asked whether the relocalization of cyclin D1 and
topoisomerase II in sanguinarine-treated cultures is
accompanied by changes in the ability of these cells to
carry out DNA synthesis. Following a 30 minute pulse of
bromodeoxyuridine (BrdU), control cultures exhibit
many strongly labeled cells, which display characteristic
patterns of S-phase BrdU immunoreactivity (Fig. 4a,b).
However, 2 hours of treatment with 5 µM sanguinarine
markedly suppresses the ability of MCF-7 cells to incorpo-
rate BrdU into their DNA. Only a few weakly staining
BrdU-positive foci remain in these cultures (Fig. 4c,d).
Cultures pulsed with BrdU after 24 hours of sanguinarine
treatment once again display many strongly labeled nuclei
(Fig. 4e,f).
Because sanguinarine is itself fluorescent, its uptake and
distribution in living MCF-7 cells were studied with vital
epifluorescence imaging methods. For these experiments,
both Hoechst 33342 and sanguinarine were added to cul-
tures to compare their uptake and distribution patterns.
Both compounds could be visualized and differentiated
using different lasers and filter sets provided with a Nikon
C1 confocal microscope. Time-lapse studies show that
cells take up Hoechst over 2 hours, resulting in a progres-
sive increase in fluorescence that is restricted to nuclei
(Fig. 5a–d). Sanguinarine also strongly labels nuclei, but
displays a number of significant differences from Hoechst.
Dose-response characteristics of MCF-7 cells treated with  sanguinarine Figure 1
Dose-response characteristics of MCF-7 cells treated 
with sanguinarine. Responses of cells to a single dose of 
sanguinarine, showing effective suppression of cell growth in 
cultures receiving 5 or 7.5 µM sanguinarine. Data points are 
expressed as percentages of the cell density at time of sangui-
narine addition (set at 100%, and called T = 0). Each data 
point is the average of three independent experiments; bars 
indicate standard error. Cultures treated with 5 and 7.5 µM 
sanguinarine for 5 and 6 days contain significantly fewer cells 
from control cultures and cultures treated with 2.5 µM san-
guinarine (asterisks; Student's t-test, p < 0.05).BMC Cell Biology 2006, 7:13 http://www.biomedcentral.com/1471-2121/7/13
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It is more rapidly taken up by cells, first becoming visible
in small cytoplasmic aggregates a few minutes after drug
addition (not shown). These aggregates decrease in inten-
sity at about the same time nuclear fluorescence increases,
and eventually only nuclear fluorescence is evident. San-
guinarine nuclear fluorescence is shorter-lived than
Hoechst, and begins to decrease in intensity after a few
hours (Fig. 5e–h). Sanguinarine nuclear fluorescence is
noticeably diminished six hours after drug addition, and
cells are essentially non-fluorescent after 24 hours of san-
guinarine treatment (data not shown).
To verify that most of the cells treated with 5 µM sangui-
narine in the immunofluorescent studies were in fact still
viable, a number of different fluorescent probes routinely
used to assess the apoptotic status of cells were used,
including Hoechst, tetramethylrhodamine methyl ester
(TMRM), calcein AM, and ethidium homodimer.
Although TMRM and ethidium homodimer both fluo-
resce red, they label different structures in living versus
dead cells: cells with intact plasma membranes exclude
ethidium homodimer and are unlabeled, whereas apop-
totic cells with compromised plasma membranes exhibit
red nuclei after incubation with this DNA-binding dye. In
contrast, mitochondria with polarized inner membranes
are strongly labeled by TMRM in living cells, whereas
dying or dead cells with depolarized mitochondria are
unlabeled by this probe. Calcein AM is hydrolyzed by
esterases and retained in living cells with intact plasma
membranes, imparting a green fluorescence, while
Sanguinarine induces long-term disruptions in cyclin D1 trafficking Figure 2
Sanguinarine induces long-term disruptions in cyclin D1 trafficking. Cultures were fixed and immunolabeled with an 
antibody to cyclin D1 (green) and counterstained with Hoechst to visualize DNA (blue). DIC, differential interference micros-
copy. (a-c) Control cells, showing that cyclin D1 labeling is restricted to nuclei, which vary in labeling intensity. (d-f) Culture 
treated with 5 µM sanguinarine for 24 hours. Note the appearance of bright cytoplasmic speckles of cyclin D1 immunofluores-
cence (arrows), while the overall nuclear labeling intensity appears to be diminished. (g-i) Culture allowed to recover in drug-
free media for 48 hours after a 24 hour pulse of 5 µM sanguinarine. Cytoplasmic deposits of cyclin D1 (arrows) are still present 
in many cells.BMC Cell Biology 2006, 7:13 http://www.biomedcentral.com/1471-2121/7/13
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Topoisomerase II, but not NuMA, is also aberrantly localized following sanguinarine treatment Figure 3
Topoisomerase II, but not NuMA, is also aberrantly localized following sanguinarine treatment. Cultures were 
fixed and double-labeled with antibodies to topoisomerase II (green), NuMA (red), and counterstained with Hoechst to visual-
ize DNA (blue). DIC, differential interference microscopy. (a-d) Control culture, showing normal distribution of topoisomer-
ase II and NuMA. Note variable labeling of nuclei with topoisomerase antibody; cytoplasmic labeling, when present, is 
homogeneous throughout the cell. In contrast, NuMA is much more uniform in its distribution throughout all nuclei. (e-h) Cul-
ture treated with 5 µM sanguinarine for 24 hours. Similar to cyclin D1, topoisomerase II is also redistributed into numerous 
cytoplasmic speckles (arrow). NuMA remains uniformly labeled in all nuclei.BMC Cell Biology 2006, 7:13 http://www.biomedcentral.com/1471-2121/7/13
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Hoechst is a cell permeant blue fluorescent DNA-binding
dye that reveals chromatin patterns in both living and
dead or dying cells. Thus, living, viable cells exhibit an
overall green cytoplasmic fluorescence, red mitochondia,
and blue nuclei with normal patterns of euchromatin and
heterochromatin, while apoptotic cells that are well along
the cell death pathway lack both the green cytoplasmic
calcein and the red mitochondrial TMRM signals, and
contain dual-labeled red and blue nuclei that display con-
densed chromatin patterns. By these criteria, most MCF-7
cells treated with 5 µM sanguinarine for 24 hours (which
are morphologically identical to the cells displaying
altered cyclin D1 and topoisomerase II trafficking in the
immunolabeling experiments), are not apoptotic (Fig. 6).
Overall, a slight variation exists between groups of cells in
both control and sanguinarine-treated cells with respect to
both the intensity and textural labeling of heterochroma-
tin by Hoechst. In the fields shown in Fig. 6d and 6h, the
sanginarine-treated group of cells appears to be somewhat
more heterochromatic and brightly stained than the con-
trols, but the converse situation often exists, depending
on the field of view. These patterns may reflect modest dif-
ferences in the ability of Hoechst to penetrate individual
MCF-7 cells or clones of cells at this concentration and
timepoint. These subtle differences are clearly distinguish-
able from the extensive nuclear alterations characteristic
of apoptosis.
Discussion
Our findings indicate that a single dose of 5 µM sangui-
narine results in a striking relocalization of cyclin D1 and
topoisomerase II from the nucleus to the cytoplasm of
MCF-7 breast cancer cells, along with an arrest of prolifer-
ation for at least six days. Previous work has largely
focused on examining the effects of sanguinarine on cell
viability at shorter timepoints [3-6]. A number of reports
have documented the ability of sanguinarine to induce
apoptosis in a number of malignant cell lines [3-5], and
evidence exists that this alkaloid may exhibit some selec-
tivity for transformed cells [6]. Although we did not spe-
cifically quantitate apoptosis in this study, a number of
tests for apoptosis indicates that sanguinarine can sup-
press MCF-7 cell growth independently of triggering
apoptosis, and that a relatively narrow window of drug
activity for this effect exists, with concentrations of sangui-
narine less than 2.5 µM resulting in little effect on cell via-
bility and proliferation rate, concentrations between 2.5
and 7.5 µM suppressing cell growth without inducing sig-
Sanguinarine transiently inhibits DNA synthesis Figure 4
Sanguinarine transiently inhibits DNA synthesis. Control and drug-treated cells were pulsed with 10 µM BrdU for 30 
minutes prior to fixation, and subsequently labeled with an antibody to BrdU (green) and counterstained with Hoechst (blue). 
(a and b) Note strong BrdU labeling of nuclei of S-phase cells. (c and d) Cells pulsed with BrdU 2 hours after the addition of 5 
µM sanguinarine to the culture medium. Note the strong suppression of BrdU labeling. (e and f) Cells cultured in the presence 
of 5 µM sanguinarine for 24 hours prior to being pulsed with BrdU. Interestingly, a number of cells again display brightly labeled 
nuclei.BMC Cell Biology 2006, 7:13 http://www.biomedcentral.com/1471-2121/7/13
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nificant levels of apoptosis, and higher concentrations
resulting in cytotoxicity and widespread cell death. Fur-
thermore, the window within which sanguinarine inhibits
cell proliferation without inducing cell death appears to
be strongly influenced by cell density, with cultures
greater than about 50% confluence exhibiting more resist-
ance to sanguinarine compared to those of lower density.
Previous reports have shown induction of apoptosis in
other cell lines at lower concentrations of sanguinarine
than those used in this study. For example, less than 1 µM
sanguinarine is able to induce apoptosis in some cell lines
[3,4]. One possible reason for this difference is that MCF-
7 cells do not express functional caspase 3 due to a dele-
tion in exon 3 [37,38], and generally show an increased
resistance to many chemotherapeutic agents [39,40]. Our
ongoing studies support the concept that other caspase 3-
expressing cell lines (e.g., LNCaP prostate cancer cells) are
indeed more sensitive to the effects of sanguinarine than
are MCF-7 cells. Interestingly, in all lines so far examined,
including a normal endothelial cell line immortalized by
transfection with SV40 large T antigen, redistribution of
cyclin D1 and topoisomerase II similar to that shown in
this report has been observed at sub-apoptotic concentra-
tions of sanguinarine (data not shown).
The relocalization of cyclin D1 and topoisomerase II from
nucleus to cytoplasm demonstrates that the normal traf-
ficking of these molecules is disrupted by sanguinarine. In
our experiments, altered cyclin D1 and topoisomerase II
trafficking takes a number of hours to become apparent,
but is long-lasting, with cytoplasmic deposits of both
molecules still evident two days after a 24 hour pulse of 5
µM sanguinarine. This does not appear to reflect a non-
specific disruption of all nuclear trafficking, as demon-
strated by the lack of a redistribution of lamin B1 and
NuMA. Furthermore, it does not appear to simply reflect
cell death, as it was observed in otherwise healthy-looking
cells three days after the application of sanguinarine.
Although a large effort has been directed toward under-
standing the importance of cyclin expression and destruc-
tion in cell cycle regulation, it is becoming clear that
regulating the trafficking and location of cyclin/CDK com-
plexes is also a critical factor in their functioning. All of the
major mitotic cyclins and their interacting CDK partners
(cyclin D, A, E and B1, and CDK1,2,4 and 6) shuttle
between nucleus and cytoplasm, but appear to do so by
distinct mechanisms. [41-50]. The importance of proper
cyclin trafficking in cell cycle control is illustrated by struc-
tural variants that display altered localization patterns.
For example, splice variants of cyclin D1 have been iden-
tified that exhibit profound differences in cell cycle regu-
latory activity [51-53]. One such splice variant, termed
D1b, is constitutively localized to the nucleus because it
does not possess the necessary threonine phosphorylation
modification at residue T286 required for nuclear export
[45]. D1b binds and activates CDK4, and is a potent cel-
Vital imaging of sanguinarine uptake and distribution in MCF-7 cells by laser-scanning confocal microscopy Figure 5
Vital imaging of sanguinarine uptake and distribution in MCF-7 cells by laser-scanning confocal microscopy. 5 
µg/ml Hoechst and 10 µM sanguinarine were simultaneously added to living cultures and images taken with both blue 
(Hoechst) and red (sanguinarine) channels every 2 minutes for two hours. (a-c) Three frames from a time lapse movie (a, b and 
c = 6, 60, and 120 minutes after drug addition, respectively), showing Hoechst fluorescence. Using the Nikon C1 software, the 
average pixel intensities of circles encompassing approximately the central third of each of 10 nuclei were charted over time 
(d). Over this timecourse, Hoechst nuclear fluorescence progressively increases. (e-g) Three frames from the same time-lapse 
movie and same timepoints shown in (a-c), demonstrating that sanguinarine uptake and disposition differs from that of 
Hoechst. Nuclei are more rapidly labeled by sanginarine, but this signal is shorter-lived, and begins to noticeably diminish after 
a few hours (h).BMC Cell Biology 2006, 7:13 http://www.biomedcentral.com/1471-2121/7/13
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Most cells treated with 5 µM sanguinarine for 24 hours are not apoptotic Figure 6
Most cells treated with 5 µM sanguinarine for 24 hours are not apoptotic. Multiparameter imaging was conducted 
with control (a-d) and sanguinarine-treated (e-h) cultures, using differential interference (DIC) microscopy (a and e), a fluores-
cein filter set to visualize calcein (green, b and f), a rhodamine filter set to detect both TMRM and ethidium homodimer (red, c 
and g), and a UV filter set to show Hoechst (blue, d and h). The same field of view is shown for each of the imaging methods for 
the control and drug-treated samples. Living cells fluoresce green and contain red mitochondria, but lack red nuclear labeling. 
In contrast, apoptotic cells do not display calcein or mitochondrial labeling, but contain nuclei with condensing chromatin that 
are both red (indicating ethidium homodimer penetration) and blue. Two apoptotic cells are present in the sanguinarine sam-
ple (arrows). The nucleus of the lower apoptotic cell consisted of a tightly condensed ball of heterochromatin, which is mostly 
out of the plane of focus in this image. Apoptotic cells can be found in both control and sanguinarine cultures, but are easily 
identifiable, even solely by DIC microscopy. Only healthy appearing, well-spread cells were used to show the redistribution of 
cyclin D1 and topoisomerase II in sanguinarine-treated cultures (Figs. 2 and 3).BMC Cell Biology 2006, 7:13 http://www.biomedcentral.com/1471-2121/7/13
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lular transforming factor [51,53]. Site-directed mutations
to the key phosphorylation site in cyclin D1 required for
nuclear import, T156, act in a dominant-negative fashion,
sequestering cyclin D1-CDK4 complexes in the cytoplasm
[54]. Our findings that cyclin D1 is relocalized to the cyto-
plasm in cultures that are blocked from proliferating by 5
µM sanguinarine suggests that sub-apoptotic concentra-
tions of this alkaloid are able to block cell growth by dis-
rupting cyclin trafficking and reducing the overall levels of
nuclear cyclin D1.
Alterations in topoisomerase II localization have been
shown to critically influence the effectiveness of topoi-
somerase poisons [35,36]. These studies demonstrate that
decreasing the nuclear:cytoplasmic ratio of topoisomerase
II reduces the extent of cleavable complex formation and
DNA damage imparted by topoisomerase poisons. At the
same time, reduction in the quantity of nuclear topoi-
somerase II could impede cell division by limiting the
ability to resolve the topological requirements of DNA
replication. Increasing the proportion of cyclin D1 and
topoisomerase II in the cytoplasm could be expected to
suppress the ability of cells to enter and complete S phase,
and sanguinarine has been reported to increase in the per-
centage of cells in G0/G1 [4].
Little information is available on the impact of sanguinar-
ine on cell cycle traverse. Although prostate carcinoma
cells were reported to accumulate in G0/G1 following san-
guinarine treatment [4], no significant effects were noted
for A431 epidermoid carcinoma cells [6]. The alkaloid
Tetrandrine induces a block early in G1 [23,25], and the
triterpenoids CDDO and ursolic acid have been shown to
decrease the number of cells in S-phase in a number of cell
lines, including breast cancer cells [19,55]. Our experi-
ments show that exposure to 5 µM sanguinarine rapidly
(within two hours) suppresses DNA synthesis in MCF-7
cells, but these cells recover at least some of their ability to
synthesize DNA 24 hours after the addition of drug. This
suggests that there may be two distinct effects of sangui-
narine on DNA synthesis, namely, a rapid and direct inhi-
bition of DNA synthesis (from which cells can recover),
followed by a longer term reduction in the number of cells
in S-phase, presumably due to some type of arrest or elic-
ited checkpoint response at another point(s) in the cell
cycle. We have not yet tested whether sanguinarine alters
the numbers of cells in S-phase following recovery, and
these two phenomenon could be reconciled if it turns out
the total numbers of cells in S-phase are reduced follow-
ing sanguinarine treatment. Sanguinarine binds to G-C
rich regions of DNA [15], and can form DNA adducts
[56]. Nick translation assays show that sanguinarine
inhibits DNA replication by polymerase I, apparently
through the formation of alkaloid-DNA complexes [17].
These interactions could underlie the rapid inhibition of
BrdU incorporation into DNA observed in this study. It is
also possible that the BrdU incorporation observed at the
24 hour timepoint reflects DNA repair. However, other
studies visualizing DNA repair by BrdU incorporation
methods show relatively few, dispersed foci of BrdU
incorporation [57], in contrast to the strong and more
uniform labeling characteristic of S-phase. The labeled
nuclei at the 24 hour timepoint in this study were rela-
tively strongly and homogeneously labeled, suggestive of
DNA synthesis rather than repair, but further experiments
are required to resolve this question.
An experimentally useful feature of sanguinarine is the
fact that it is a fluorescent compound and can be detected
by epifluorescence microscopy. This approach showed
that sanguinarine rapidly (within 5–10 minutes) accumu-
lates in the nucleus of HeLa cells, and nuclei are still fluo-
rescent 3 hours after sanguinarine is washed out of the
medium [58]. Our results demonstrate that sanguinarine
is also readily taken up by MCF-7 cells and concentrated
in the nucleus. However, we observed a distinct reduction
in fluorescence intensity after a few hours, and cells cul-
tured overnight in sanguinarine display essentially no
nuclear fluorescence, which can be regained by the addi-
tion of fresh sanguinarine (data not shown). This behav-
ior is different from that of Hoechst 33342, which
progressively labels nuclei over the same time period. The
finding that the effects of sanguinarine on cyclin D1 and
topoisomerase II trafficking last far longer than the
nuclear fluorescence of this alkaloid can be detected sug-
gests that the transient presence of sanguinarine may have
long-lasting effects on nuclear transport mechanisms. An
alternative possibility is that non-fluorescent metabolites
of sanguinarine persist that retain an ability to disrupt
nuclear-cytoplasmic trafficking.
Conclusion
Our results lead us to propose the following model for the
events that occur when cells are exposed to sub-apoptotic
concentrations of sanguinarine. Sanguinarine is taken up
by cells and concentrated in the nucleus within minutes,
where it rapidly inhibits DNA synthesis. After a few hours,
sanguinarine begins to be metabolized, loses its fluores-
cence characteristics, and its nuclear effects diminish,
resulting in the ability of cells to again synthesize DNA.
However, the cellular events set into play by the initial
presence of sanguinarine lead to a much longer-lived dis-
ruption of cyclin D1 and certain other nuclear protein
trafficking patterns, resulting in extended cell cycle arrest
and inhibition of cell proliferation. In terms of develop-
ment as a possible cancer chemotherapeutic, this model
suggests that sanguinarine may help suppress malignant
cell growth even at sub-apoptotic concentrations. It will
be interesting and important to transfer these experimentsBMC Cell Biology 2006, 7:13 http://www.biomedcentral.com/1471-2121/7/13
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to an in vivo setting to determine if similar responses occur
in malignant cells in an intact animal.
Methods
Cell culture
MCF-7 cells (the kind gift of Dr. Merry Jo Oursler, Depart-
ment of Orthopedics, Mayo Clinic, Rochester, MN) were
grown in Dulbecco's modified Eagle's medium (GIBCO,
Grand Island, NY) and 7.5% Fetal Clone III (HyClone,
Logan, UT) in a 5% CO2 atmosphere at 37°C. Cells were
passaged by trypsinization using standard methods; all
experiments were conducted with cultures between 25–
75% confluency, and in log-phase growth.
Cell proliferation measurements
Sulforhodamine B assays were conducted to measure the
effects of sanguinarine on the proliferation of MCF-7 cells.
Cells were seeded at a concentration of 2.5 × 104 cells/ml
in 24-well plates, and allowed to recover for 2 days prior
to drug addition. Sanguinarine (>98% pure, Sigma Chem-
ical Co., St. Louis, MO) was diluted to 0.5 mM in DMEM
from a 50 mM stock solution in DMSO, and this diluted
stock solution added to multiwell plates to a final concen-
tration of 2.5, 5, or 7.5 µM. Control wells received diluted
vehicle only, corresponding to the amount present in the
7.5 µM sanguinarine wells (i.e., 15 µl of a 1% DMSO solu-
tion). At the time of drug or vehicle only addition, the
medium from one column (4 wells) was aspirated and the
wells subsequently rinsed with DMEM followed by sterile
distilled water. The water was aspirated, and the plate
replaced in the incubator (these wells represent the cell
density at the time of drugging, called T = 0). At days 2, 3,
4, 5 and 6 following sanguinarine addition, this process
was repeated for another column of wells (each column
consisting of control, 2.5, 5, and 7.5 µM sanguinarine-
treated wells). After the last column in a dish was proc-
essed (on day 6), the entire air-dried plate was fixed with
absolute methanol containing 1% acetic acid (at -10°C)
for 30 minutes, the methanol decanted, and the plate
again air-dried. Sulforhodamine B (0.5% in 1% acetic
acid) was added to each well, and the plate incubated at
35°C for 1 hour. Plates were rinsed with 1% acetic acid,
air-dried, and the bound dye eluted with 1 ml of 10 mM
Tris buffer, pH 10. The absorbance was measured in a
spectrophotometer at 540 nm; the amount of dye released
is proportional to the number of cells present in the dish,
and is a reliable indicator of cell proliferation.
Immunofluorescence labeling methods
Cells were seeded on glass coverslips in 6-well plates at a
density of 2.5 × 104 cells/ml, and allowed to recover for
two days prior to drug addition. 5 µM Sanguinarine was
added as described above for various lengths of time, after
which the cells were fixed by plunging the coverslips into
cold (-10°C) absolute methanol. In some experiments,
sanguinarine was washed out after 24 hours (via 3
exchanges of feeding solution), and further cultured in
drug-free medium for another 24 or 48 hours prior to fix-
ation. Cells were prepared for immunolabeling by rehy-
dration in PBS containing 0.05% Tween-20 (PBST), and
subsequently blocked with 1% nonfat powdered milk dis-
solved in PBST for 1 hour at 37°C. Cells were labeled with
antibodies to cyclin D1 (Santa Cruz Biotechnology Inc.,
Santa Cruz, CA) topoisomerase II (the kind gift of Dr.
Scott Kaufmann, Mayo Clinic, Rochester, MN), or NuMA
(the kind gift of M. Snyder, Yale University, New Haven,
NY) for 1 hour at 37°C, washed with three changes of
PBST, and incubated in the appropriate fluorescently-con-
jugated secondary antibodies (goat-anti-mouse- or goat-
anti-rabbit-fluroescein or Texas Red, Jackson Immunore-
search, Malvern, PA), containing 5 µg/ml Hoechst 33342
(Sigma Chemical Co.) for 1 hour at 37°C. After 3 final
PBST washes, coverslips were mounted in an anti-fade
medium (90% glycerol, 10% 0.5 M 3- [cyclohexylamino]-
1-propanesulfonic acid, buffer pH 9.0, containing 0.1%
paraphenylenediamine and 0.1% 1,4-diazabicyclo-
[2.2.2]octane) on glass slides, and examined by routine
epifluorescence or laser-scanning confocal microscopy.
BrdU labeling
After either 2 or 24 hours of treatment with 5 µM sangui-
narine, cells were pulse-labeled with 10 µM Bromodeoxy-
uridine (BrdU; Sigma) for 30 minutes and then fixed in
cold (-10°C) absolute methanol. For BrdU labeling, cells
were rehydrated with PBST and treated with 2 N HCl for
20 minutes at room temperature. Cells were then washed
five times with PBST, and incubated in PBST containing
0.5% non-fat powdered milk for 30 minutes at 37°C.
Anti-BrdU antibody (G3G4, Developmental Studies
Hybridoma Bank, Iowa City, IA) was added for 1 hour at
37°C, and cells washed three times in PBST and incubated
in goat-anti-mouse antibody conjugated to Texas Red
(Jackson Immunoresearch) containing 5 µg/ml Hoechst
33342 for 1 hour at 37°C. Coverslips were finally washed
in PBST and mounted as described above.
Vital cell imaging
Cells were seeded into 35 mm glass-bottom Petri dishes
(MatTek Inc., Amherst, MA) at a density of 2.5 × 104/ml,
and allowed to recover for 2 days prior to use. To visualize
and compare cellular uptake of sanguinarine and Hoechst
dye, the normal culture medium (DMEM/7.5% FBS) was
exchanged with a 1:1 mixture of DMEM and Liebovitz's L-
15 medium containing 5% FBS (which maintains a neu-
tral pH in the absence of CO2) and placed on the stage of
a Nikon C1 confocal microscope (at room temperature).
Laser excitation and PMT gain were set at values previ-
ously found to be suitable for imaging sanguinarine and
Hoechst in cells incubated in these compounds for 2–4
hours, and time-lapse acquisition started (sequentialBMC Cell Biology 2006, 7:13 http://www.biomedcentral.com/1471-2121/7/13
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scanning every 2 minutes for 2–4 hours). Sanguinarine
(10 µM) and Hoechst 33342 (5 µg/ml) were then simul-
taneously added to the dishes from freshly diluted 100×
stock solutions prepared in DMEM. Hoechst fluorescence
was visualized using a Coherent VioFlame solid state laser
(20 mW at 405 nm) and a 480 nm dichroic long pass,
with a 450/35 nm band pass for the blue channel (PMT
1); sanguinarine was visualized using a Spectra Physics
Krypton-Argon Model 163C polarized laser (40 mW at
488 nm) and a 545 nm dichroic long pass, with a 605/75
band pass for the red channel (PMT 2). To test for apop-
tosis, cells seeded into glass-bottom dishes as described
above were treated with a a cocktail of fluorescent probes,
including Hoechst 33342 (5 µg/ml), 100 nM tetramethyl-
rhodamine methylester (TMRM; Molecular Probes,
Eugene, OR), 2 µM calcein AM (Molecular Probes), and 2
µM ethidium homodimer (Molecular Probes) for 45 min-
utes prior to imaging on an inverted fluorescent micro-
scope.
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